MagForce AG Announces that Cologne University Hospital has Initiated Commercial NanoTherm(TM) Treatments for Brain Cancer

BERLIN & CARSON CITY, Nev.--()--MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Center for Integrated Oncology at Cologne University Hospital, headed by Prof. Dr. med. Roland Goldbrunner, has initiated NanoTherm(TM) therapy in the commercial setting for the treatment of brain cancers in addition to the ongoing post-marketing study.

“We continue to be on track with our preparations for the approval process in the U.S. for both brain and prostate cancer”

This represents the inauguration of the third clinic in Germany that offers the benefit of MagForce's NanoTherm(TM) therapy for brain cancer patients in addition to the University Hospitals in Münster and Kiel.

"With Cologne we have established another renowned medical center for treating brain cancer patients with our proprietary NanoTherm(TM) therapy also in the commercial setting. This expansion provides more geographic opportunites for treatment within Germany. We are very happy to see increasing interest by private pay patients and also with the successful interaction with the key opinion leaders in the medical community," commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA, Inc.

Additional to the increasing commercial business in Europe, the key focus of MagForce is on the US market.

"We continue to be on track with our preparations for the approval process in the U.S. for both brain and prostate cancer," Dr. Ben J. Lipps added.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Language:       English    
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail:

info@magforce.com

Internet:

www.magforce.com

ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt

Contacts

MC Services AG
Anne Hennecke
P +49 211 529252-22
F +49 211 529252-29
E-mail: anne.hennecke@mc-services.eu

MagForce AG